MedTrace Logo

Hydroxychloroquine, Azithromycin in the Treatment of Covid-19

NCT04405921 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-06-19

No results posted yet for this study

Summary

This study investigates the efficay and tolerance of 5-days course of hydroxychloroquine or hydroxychloroquine and azithromycin of patients with COVID-19 infection. The investigators will undertake a randomized, double-blind, controlled Trial in the region of Sousse Tunisia

Conditions

Interventions

DRUG

Hydroxychloroquine 200 Mg Oral Tablet

orally or via gastric tube

DRUG

Azithromycin 250 MG

orally or via gastric tube

Sponsors & Collaborators

  • Centre Hôpital Universitaire Farhat Hached

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2020-12-31
Completion
2021-03-31

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405921 on ClinicalTrials.gov